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other centres with the request to check if their own 
inventory was complete. The classification was checked 
independently by two senior investigators. 
 
Results: Out of the 20 centres invited to participate in the 
study 15 took part in the final study, 8 of which were 
academic and 7 non-academic.As shown in the table below, 
the number of innovations in academic centres was higher 
but not significantly different from non-academic centres. An 
academic centre implemented on average 17 (range 12-27) 
innovations per year and a non-academic centre on average 
of 14 (range 10-18). Treatment innovation (e.g. breath hold 
mamma, IGRT) was the most frequently implemented 
innovation (n=102) followed by organisational innovation 
(e.g. starting a satellite, new Electronic Patient 
Record)(n=71) and technological innovation (e.g. IMRT, 
technological new linacs)(n=61). In each innovation category 
an academic centre is performing the highest number of 
innovations. 
 
 
 
Conclusion: Radiotherapy centres in the Netherlands 
implement on average 16 innovations per year in their 
department; this number is not significantly different for 
academic or non-academic centres. These numbers confirm 
that radiotherapy is a very dynamic and innovative discipline. 
In our next study we will investigate what are the key drivers 
for innovation.  
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Purpose or Objective: The efficiency in the translation of 
scientific discoveries into clinical practices in general 
healthcare is low. Previous research concluded that 
approximately 5 % of peer–reviewed papers concern findings 
which are routinely implemented. We hypothesize that 
implementation rates in radiotherapy will be higher, in 
particular in an institution which has an integrated strategy 
for research, valorisation and patient care, and has a data 
centre for clinical trials including a software development 
team.Our aim is to study the efficiency of research 
implementation in the clinic either in routine or in clinical 
trials in a large radiotherapy institution over a period of 4 
years. The research questions are two-fold: 1) what is the 
percentage of published findings routinely implemented in 
clinical practice? And 2) what is the rate of clinical testing of 
laboratory and technological published findings? 
Furthermore, we have tried to identify the facilitators and 
barriers within this process. 
 
Material and Methods: The scientific publications of 
researchers of our own institute were listed for the period 
from 2008-2011 (4 years), categorized as shown in the table 
below. From the literature we listed the facilitators and 
barriers in the implementation process. We asked clinicians 
of the tumour expert groups if the published study had yet 
been implemented into clinical practice or clinical trials, and 
which facilitators or barriers were applicable. This has been 
verified by an independent investigator. We calculated 
implementation rates and the frequency of mentioned 
facilitators and barriers. Furthermore the head of research 
scored whether pre-clinical and technological scientific 
publications had been tested in clinical trials. This was 
checked independently by two senior investigators.  
 
Results: Internal researchers published 244 papers of which 
79 (32%) were clinical (technological) papers. In total, 45/244 
papers (18%) were routinely implemented; of the 79 clinical 
(technological) papers, this percentage was even higher: 33% 
(26/79). Overall 73/244 (30%) papers (all technical or 
laboratory papers ) were tested in a clinical environment, 
mostly in the context of a research project (Table).The main 
facilitator was level of evidence, and the main barriers were 
workload and high complexity (Figure).  
 
 
 
 
Conclusion: The efficiency in translation of published 
research in radiotherapy in reaching the clinic was much 
higher than in general healthcare. Level of evidence was an 
important facilitator, whereas high workload and complexity 
were important barriers. The next step will be to look at the 
time needed for implementation and to investigate 
implementation rate in other centres. We propose that the 
rate of clinical implementation of published research 
findings, routinely or in trials, should be a quality indicator of 
integrated research-patient care organisation such as a 
comprehensive cancer centre.  
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Purpose or Objective: As of 1 July 2015 The 
ClinicalTrials.gov database was searched for interventional 
phase-3 trials in radiotherapy with a primary completion date 
before 1 January 2013. According to the 2007 Act of the 
FDAAA results of applicable clinical trials are due not later 
than 12 months after the primary completion date. Our 
objective was to determine how many of these trials have 
not been published a deposition of their results within the 
register yet. 
 
Material and Methods: A first study sample consisted of 802 
interventional phase-3 clinical trials with a primary 
completion date before 1 January 2013. We also took a 
sample which was a subset of the former one, taking into 
account only the interventional phase-3 clinical trials with a 
study start as of 1 January 2008; the main reason was to see 
if those trials starting after the 2007 Act publish more results 
within the register as the trials registered before the 2007 
Act was passed. 
 
Results: In our first study sample, a total of 655 trials 
(81.7%) did not deposit a summary result. Clinical Trials 
starting after the 2007 Act was passed did not do any better: 
422 out of 552 (76.4%) haven’t published a deposition of their 
results within the register. We further analyzed our search 
results taking into account the cancer subtype. The 
percentages of unpublished results for our second study 
sample were the following: Gastric (68%), Rectal (64%), 
Bladder (90%), Sarcoma (70%), Linfoma (78%), Esophagus 
(92%), Cervix (80.6%), Astrocitoma (70%), Testicular (100%), 
Skin (89.5%), Eye (47%), Anal (100%), Palliative (75%), 
Glioblastoma (62.5%), Breast (78%), Lung (73.7%), Head&Neck 
(74.6%), Prostate (68. %). 
 
Conclusion: Our results show that most trials do not report 
results, even if they are forced to do so after the 2007 Act. 
This means that a large number of study participants were 
exposed to the risks of trial participation without the 
supposed benefits that sharing and publishing results would 
have for future generations of patients. 
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Purpose or Objective: The aim of this prospective study was 
to determine any changes in brain metastases or resection 
cavity volumes between the planning MRI and radiosurgical 
(RS) treatment and if these impacted on management or led 
to an alteration of the RS plan. 
 
Material and Methods: 33 patients with 42 metastases and 12 
tumour resection cavities underwent a planning MRI (MRI-1) 
which was fused to the planning CT. GTV (metastasis) or CTV 
(cavity) were contoured from the T1 and T2 post-gadolinium 
MRI. The GTV/CTV had a 2mm circumferential expansion 
creating a PTV with a plan generated. In addition, a 
verification MRI (MRI-2) was performed 24-48 hours prior to 
RS with volumes re-contoured on MRI-2 (verGTV/verPTV). The 
GTV/CTV and PTV volume changes between MRI-1 and MRI-2 
were recorded and the original plan assessed for coverage of 
the verPTV. A change in plan or management based on MRI-2 
was recorded. 
 
Results: Patient and tumour characteristics are shown in 
Table 1. The median time between MRI-1 and MRI-2 was 7 
days with 27 patients (82%) having 14 days or less and 22 
patients (66%) with 7 days or less. Changes in GTV/CTV and 
PTV volumes between MRI-1 and MRI-2 are shown in Figure 1. 
19 (58%) patients required a change in management based on 
changes in lesions on MRI-2 including: re-planning of RS, or a 
change in treatment to whole-brain radiotherapy (WBRT), 
surgery or best supportive care (BSC). Per lesion, 30 out of 54 
lesions (56%) required re-planning based on MRI-2 including 5 
(42%) cavities and 25 (60%) metastases. 2 patients had rapid 
progression with lepto-meningeal disease diagnosed on MRI-2 
and received WBRT. 1 patient (previously received WBRT) 
had a rapid increase in lesion size and number, with an 
additional 9 lesions noted on MRI-2 and received BSC. 
Reasons for re-planning included: increase in volume (27 
lesions) with 25 verGTV lying outside the original PTV and 2 
touching the original PTV; 2 lesions with a reduction in 
verGTV/verPTV volumes, and 3 patients with an increase in 
the number of metastases or leptomeningeal disease on MRI-
2. 
 
Conclusion: This study is the first to demonstrate changes in 
brain metastases volume from planning MRI to RS treatment, 
where changes often occurred with an interval of 7 days or 
less. An MRI performed within 24-48 hours of RS led to re-
planning or a change in management in more than 50% of 
patients. Therefore, even a short interval between planning 
MRI and RS may result in a geographical miss or over 
treatment, emphasising the need for efficient planning 
processes. 
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Purpose or Objective: The aim of this study was an 
evaluation of a toxicity and an early effectiveness of prostate 
cancer patients CyberKnife based radioablation.  
 
Material and Methods: 350 PC patients (186 Low Risk, 164 
Intermediate Risk) aged from 53 to 83 (mean 69) irradiated 
with CK every other day (fd 7.25Gy, TD 36.25Gy, OTT 9 
days). Before the treatment start PSA varied from 0.3 to 19.5 
(median 7.5) and T stage from T1c to T2c. Mean prostate 
dimensions were 42.6x37.2x41.1mm. FU ranged to 48 months 
(mean 12). Directly after the treatment, 1, 4, 8 months later 
and the next every 6 months, the percentage of patients with 
Androgen Deprivation Therapy (ADT), GI (gastro-intestinal) 
and GU (genito-urinary) toxicity (acute up to the 4th month 
and the next late) using the EORTC/RTOG scale and PSA 
concentration were checked.  
 
Results: The percentage of patients without ADT increased 
from 42.6% to 100% 32 months later. The maximal percentage 
of acute G3 adverse effects was 0.5% for GI, 0.6% for GU and 
G2 – 1.9% for GI and 6.0% for GU. No G3 late toxicity was 
observed. The maximal percentage of late G2 toxicity was 
0.5% for GI and 3.0% for GU. PSA median decreased from 2.2 
to 0.2 ng/ml during FU. One patient relapsed (18 months 
after RT- next treated with salvage BT) and one developed 
metastasis in lymphatic node (treated next with salvage CK). 
The detailed results are presented in the Table.  
 
 
 
 
 
 
 
 
 
 
 
 
 
